VACF                                              endometrium(52)
 _________________________________________________________________
  vincristine..... 1.5 mg IV day 1.
  adriamycin...... 40 mg/sqm IV day 1.
  cytoxan......... 500 mg/sqm IV day 1.
  fluorouracil.... 500 mg/sqm IV on days 2 and 3.
  FREQUENCY....... Repeat cycles at 3 week intervals for at least 
                   four courses.


  reference...
    Kauppila A.  Janne O.  Kujansuu E.  Vihko R. Treatment of 
    advanced endometrial adenocarcinoma with a combined cytotoxic 
    therapy. Predictive value of cytosol estrogen and progestin 
    receptor levels. Cancer.  46(10):2162-7, 1980 Nov 15. 
  abstract...
    Twenty patients with advanced or recurrent endometrial 
    adenocarcinoma were treated with combination chemotherapy 
    consisting of Adriamycin, cyclophosphamide, 5-fluorouracil, 
    and vincristine at three-week intervals. A minimum of four 
    treatment courses was given in each case. There were five 
    total and five partial responses (50% favorable response 
    rate); progression of the disease was evident in seven cases 
    (35%). Lung metastases responded significantly better (P < 
    0.01) than other lesions: seven out of nine lung metastases 
    showed an objective remission, whereas only two out of 11 
    tumors in pelvic, abdominal, or retroperitoneal space 
    responded. The response rate did not correlate with histologic 
    grade of tumor differentiation, or the performance state and 
    age of the patient. Cytosol estrogen and progestin receptor 
    levels were measured in 15 cases from the carcinomatous 
    endometrial tissue prior to therapy. Ten patients with low 
    receptor values (estrogen and/or progestin receptors below 30 
    fmol/mg cytosol protein) had a significantly (P < 0.025) 
    greater response rate (70%) than did patients with higher 
    receptor values (both receptors above 30 fmol/mg protein, 
    response rate 20%). Determination of only one of the two 
    receptors did not differentiate the patients equally well, 
    although the response rate tended to be better (0.05 < P < 
    0.1) in patients with a low level of either estrogen or 
    progestin receptor (67% response rate) when compared with a 
    33% response rate in patients with a high level of the 
    corresponding receptor. Our results suggest that the 
    measurement of cytosol steroid hormone receptors has the 
    potential to serve as a suitable indicator for selection of 
    endocrine or nonhormonal chemotherapy for patients with 
    advanced endometrial adenocarcinoma.